Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization

被引:30
作者
Buchli, R [1 ]
VanGundy, RS
Hickman-Miller, HD
Giberson, CF
Bardet, W
Hildebrand, WH
机构
[1] Pure Prot LLC, Oklahoma City, OK 73104 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA
关键词
D O I
10.1021/bi048580q
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Measuring the interaction of class I human leukocyte antigens (HLA) and their peptide epitopes acts as a guide for the development of vaccines, diagnostics, and immune-based therapies. Here, we report the development of a sensitive biochemical assay that relies upon fluorescence polarization to indicate peptide interactions with recombinant soluble HLA proteins. It is a cell- and radioisotope-free assay that has the advantage of allowing the direct, real-time measurement of the ratio between free and bound peptide ligand in solution without separation steps. Peptide/HLA assay parameters were established using several HLA A*0201-specific fluorescein isothiocyanate-labeled peptides. Optimal loading of synthetic peptides into fully assembled soluble HLA-A*0201 complexes was enabled by thermal destabilization at 53 degreesC for 15 min, demonstrating that efficient peptide exchange does not require the removal of endogenous peptides from the reaction environment. An optimal ratio of three beta-2 microglobulin molecules per single HLA heavy chain was determined to maximize peptide binding. Kinetic binding studies indicate that soluble HLA-A*0201/peptide interactions are characterized by a range of moderate k(on) values (1 x 10(4) to 8.7 x 10(4) M-1 s(-1)) and slow k(off) values (1.9 x 10(-4) to 4.3 x 10(-4) s(-1)), consistent with parameters for native HLA molecules. Testing of the A*0201 -specific peptides with 48 additional class I molecules demonstrates that the unique peptide binding behavior of individual HLA molecules is maintained in the assay. This assay therefore represents a versatile tool for characterizing the binding of peptide epitopes during the development of class I HLA-based vaccines and immune therapies.
引用
收藏
页码:14852 / 14863
页数:12
相关论文
共 74 条
[1]   BETA-2-MICROGLOBULIN IS NOT REQUIRED FOR CELL-SURFACE EXPRESSION OF THE MURINE CLASS-I HISTOCOMPATIBILITY ANTIGEN H-2DB OR OF A TRUNCATED H-2DB [J].
ALLEN, H ;
FRASER, J ;
FLYER, D ;
CALVIN, S ;
FLAVELL, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (19) :7447-7451
[2]   DOMAIN INTERACTIONS OF H-2 CLASS-I ANTIGENS ALTER CYTO-TOXIC T-CELL RECOGNITION SITES [J].
ALLEN, H ;
WRAITH, D ;
PALA, P ;
ASKONAS, B ;
FLAVELL, RA .
NATURE, 1984, 309 (5965) :279-281
[3]  
Aucouturier P, 1983, Diagn Immunol, V1, P310
[4]   Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: Implications for TCR signaling [J].
Baker, BM ;
Gagnon, SJ ;
Biddison, WE ;
Wiley, DC .
IMMUNITY, 2000, 13 (04) :475-484
[5]   PRODUCTION OF MONOCLONAL ANTIBODIES TO GROUP-A ERYTHROCYTES, HLA AND OTHER HUMAN CELL-SURFACE ANTIGENS - NEW TOOLS FOR GENETIC-ANALYSIS [J].
BARNSTABLE, CJ ;
BODMER, WF ;
BROWN, G ;
GALFRE, G ;
MILSTEIN, C ;
WILLIAMS, AF ;
ZIEGLER, A .
CELL, 1978, 14 (01) :9-20
[6]   HLA-A2 SUBTYPES ARE FUNCTIONALLY DISTINCT IN PEPTIDE BINDING AND PRESENTATION [J].
BAROUCH, D ;
FRIEDE, T ;
STEVANOVIC, S ;
TUSSEY, L ;
SMITH, K ;
ROWLANDJONES, S ;
BRAUD, V ;
MCMICHAEL, A ;
RAMMENSEE, HG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (06) :1847-1856
[7]   PEPTIDE BINDING TO EMPTY HLA-B27 MOLECULES OF VIABLE HUMAN-CELLS [J].
BENJAMIN, RJ ;
MADRIGAL, JA ;
PARHAM, P .
NATURE, 1991, 351 (6321) :74-77
[8]   Thermodynamic and kinetic analysis of a peptide-class I MHC interaction highlights the noncovalent nature and conformational dynamics of the class I heterotrimer [J].
Binz, AK ;
Rodriguez, RC ;
Biddison, WE ;
Baker, BM .
BIOCHEMISTRY, 2003, 42 (17) :4954-4961
[9]   Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants - Implications for susceptibility to spondylarthropathies [J].
Boisgerault, F ;
Tieng, V ;
Stolzenberg, MC ;
Dulphy, N ;
Khalil, I ;
Tamouza, R ;
Charron, D ;
Toubert, A .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (12) :2764-2770
[10]  
BURSHTYN DN, 1993, J IMMUNOL, V151, P3082